No Data
No Data
Cracking The Code: Understanding Analyst Reviews For Ovid Therapeutics
Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Ovid Therapeutics (NASDAQ:OVID) in the last three months.The following table summarizes their re
Ovid Therapeutics Is Maintained at Neutral by Citigroup
Ovid Therapeutics Is Maintained at Neutral by Citigroup
Citigroup Maintains Neutral on Ovid Therapeutics, Lowers Price Target to $3.5
Citigroup analyst Yigal Nochomovitz maintains Ovid Therapeutics (NASDAQ:OVID) with a Neutral and lowers the price target from $4 to $3.5.
Express News | Ovid Therapeutics Inc : Citigroup Cuts Target Price to $3.5 From $4
B. Riley Securities Initiates Ovid Therapeutics With Buy Rating, $9 Price Target
Ovid Therapeutics (OVID) has an average rating of buy and price targets ranging from $4 to $11, according to analysts polled by Capital IQ.
Express News | Ovid Therapeutics Inc : B. Riley Initiates Coverage With Buy Rating; Price Target $9
loading...
No Data